Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Research Highlight
  • Published:

Migraine

CGRP-targeting antibodies reduce migraine frequency

Nature Reviews Neurology volume 14, page 63 (2018)Cite this article

Subjects

Access through your institution
Buy or subscribe

The neuropeptide CGRP is found in trigeminal nerve fibres surrounding intracranial blood vessels, where it functions as a vasodilator. CGRP is released from these nerve fibres during migraine attacks and has been shown to induce headaches in healthy individuals. Such observations have prompted a concerted effort to explore CGRP as a target for migraine therapy.

In the first of the two new trials, Stephen Silberstein and colleagues tested fremanezumab — a humanized mAb that targets CGRP — in 1,130 patients with chronic migraine. Following a 4-week baseline phase, the participants were randomly allocated to monthly or quarterly subcutaneous injections of the mAb (n = 379 and n = 376, respectively) or to monthly injections of a placebo (n = 375) over a period of 12 weeks.

This is a preview of subscription content, access via your institution

Access options

Access through your institution

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Silberstein, S. D. et al. Fremanezumab for the preventive treatment of chronic migraine. N. Engl. J. Med. 377, 2113–2122 (2017)

    Article  CAS  Google Scholar 

  2. Goadsby, P. J. et al. A controlled trial of erenumab for episodic migraine. N. Engl. J. Med. 377, 2123–2132 (2017)

    Article  CAS  Google Scholar 

Download references

Authors
  1. Heather Wood
    View author publications

    Search author on:PubMed Google Scholar

Related links

Related links

Related links in Nature Research

Ho, T. W. et al. CGRP and its receptors provide new insights into migraine pathophysiology. Nat. Rev. Neurol. 6, 573–582

Related links in Nature Research

Ashina, M. et al. Human models of migraine — short-term pain for long-term gain. Nat. Rev. Neurol. 13, 713–724 (2017)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wood, H. CGRP-targeting antibodies reduce migraine frequency. Nat Rev Neurol 14, 63 (2018). https://doi.org/10.1038/nrneurol.2017.177

Download citation

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/nrneurol.2017.177

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing